Tan Seng-Lai, Pause Arnim, Shi Yuguang, Sonenberg Nahum
Infectious Diseases Research, Eli Lilly and Company, Indianapolis, Indiana 46285, USA.
Nat Rev Drug Discov. 2002 Nov;1(11):867-81. doi: 10.1038/nrd937.
Chronic infection with hepatitis C virus (HCV) is an emerging global epidemic. The development of effective HCV antiviral therapeutics continues to be a daunting challenge owing to the absence of adequate animal models and tissue-culture systems for analysis and propagation of the virus. Despite these obstacles, inhibitors of the replicative elements of HCV, immune modulators and non-specific hepatoprotective agents are being pursued and exciting progress has been made. Successful therapeutic intervention of HCV will probably require combination approaches and new approaches, including host drug discovery targets.
丙型肝炎病毒（HCV）的慢性感染正成为一种全球性的新流行病。由于缺乏用于该病毒分析和繁殖的合适动物模型及组织培养系统，开发有效的HCV抗病毒治疗药物仍然是一项艰巨的挑战。尽管存在这些障碍，但人们仍在探索HCV复制元件抑制剂、免疫调节剂和非特异性肝保护剂，并且已经取得了令人振奋的进展。成功治疗HCV可能需要联合治疗方法以及新的方法，包括寻找宿主药物发现靶点。
